Related Experiment Video
Updated: Aug 28, 2025

Systematic Scoring Analysis for Intestinal Inflammation in a Murine Dextran Sodium Sulfate-Induced Colitis Model
Published on: February 14, 2021
Searching for a Consensus Among Inflammatory Bowel Disease Studies: A Systematic Meta-Analysis
Lama Izzat Hasan Abdel-Rahman1, Xochitl C Morgan1
1Department of Microbiology and Immunology, University of Otago, Dunedin, New Zealand.
Gut microbiome studies in inflammatory bowel disease (IBD) show inconsistent results. Sample type significantly impacts findings, with stool samples being more reliable for Crohn's disease (CD) research.
Area of Science:
- Microbiome research
- Gastroenterology
- Inflammatory Bowel Disease (IBD)
Background:
- Numerous studies have investigated the gut microbial ecology in Crohn's disease (CD) and ulcerative colitis (UC).
- However, findings regarding IBD-associated taxa and ecological effect sizes lack consistency across studies.
- This variability complicates the understanding of IBD pathogenesis and microbiome-based diagnostics.
Approach:
- A systematic literature search of PubMed and Google Scholar was conducted.
- A meta-analysis of 13 studies was performed to evaluate the impact of sample types (stool, biopsy, lavage) on IBD gut microbiome research.
- Uniform bioinformatic methods were applied to all primary data for standardized analysis.
Key Points:
- Reduced alpha diversity was a consistent finding in both CD and UC, more pronounced in CD.
- While disease significantly influenced beta diversity, sample type had a greater effect size than the disease itself.
- Fusobacterium was the most consistently identified genus in CD, but other disease-associated genera varied significantly between studies.
- Stool-based studies exhibited lower heterogeneity compared to biopsy-based studies, particularly for CD.
Conclusions:
- Sample type variation is a critical factor contributing to inconsistencies in IBD gut microbiome studies.
- Careful consideration of sample type during study design is essential for robust and reproducible research.
- Stool samples are recommended over biopsy samples for CD studies due to lower heterogeneity, leading to more reliable results.
Related Concept Videos
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Chronic Bowel Disorders: Introduction
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

